A community health concern: respiratory syncytial virus and children.
Miller
Susan
S
Rush-Copley Medical Center, Aurora, IL, USA. susan6664@aol.com
D017677:Age Distribution; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use*; D002675:Child, Preschool; D003153:Community Health Services / Q000191:economics; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015994:Incidence; D007223:Infant; D007273:Injections, Intramuscular; D008297:Male; D000069455:Palivizumab; D017410:Practice Guidelines as Topic; D011322:Primary Prevention / Q000191:economics / Q000379:methods; D018357:Respiratory Syncytial Virus Infections / Q000191:economics / Q000453:epidemiology* / Q000517:prevention & control*; D012136:Respiratory Syncytial Viruses / Q000187:drug effects* / Q000302:isolation & purification; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000453:epidemiology / Q000821:virology; D018570:Risk Assessment; D014481:United States
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab